Amarin Corporation plc (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AMRN Nasdaq 2834 http://www.amarincorp.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amarin Corporation plc (ADR)

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) - Mar 16th, 2023 12:00 pm
Amarin Announces Board Departures - Mar 6th, 2023 9:05 pm
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome - Mar 6th, 2023 2:37 pm
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC - Mar 6th, 2023 1:00 pm
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event - Mar 5th, 2023 3:21 pm
Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript - Mar 3rd, 2023 4:09 pm
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates - Mar 2nd, 2023 6:23 pm
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales - Mar 2nd, 2023 4:44 pm
Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021) - Mar 2nd, 2023 10:55 am
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up - Mar 1st, 2023 4:02 pm
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript - Mar 1st, 2023 4:00 pm
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 1st, 2023 12:00 pm
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales - Feb 28th, 2023 4:11 pm
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide - Feb 28th, 2023 3:39 pm
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders - Feb 28th, 2023 3:38 pm
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand - Feb 28th, 2023 1:00 pm
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements - Feb 27th, 2023 9:29 pm
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC - Feb 27th, 2023 1:00 pm
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives - Feb 27th, 2023 12:15 pm
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4 - Feb 24th, 2023 4:52 pm